ACM
KYMR icon

ADAR1 Capital Management’s Kymera Therapeutics KYMR Stock Holding History

ADAR1 Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,366
Closed -$583K – 244
2025
Q2 		$583K Buy
13,366
+3,366
+34% +$116K 0.09% 110
2025
Q1 		$274K Hold
10,000
– – 0.05% 131
2024
Q4 		$402K Sell
10,000
-1,856
-16% -$83.8K 0.08% 121
2024
Q3 		$561K Sell
11,856
-38,770
-77% -$1.71M 0.09% 108
2024
Q2 		$1.51M Buy
50,626
+34,626
+216% +$1.2M 0.29% 54
2024
Q1 		$643K Buy
+16,000
New +$572K 0.15% 73

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

ADAR1 Capital Management's KYMR Position: Q3 2025 in Review

ADAR1 Capital Management sold out of Kymera Therapeutics (KYMR) in Q3 2025, closing a stake of 13,366 shares — an estimated $583K sold.

ADAR1 Capital Management first reported a position in KYMR in Q1 2024 and held it in 6 quarters. The position peaked at $1.51M in Q2 2024. 210 funds tracked by Wall St. Rank hold KYMR as of Q3 2025.

  • ADAR1 Capital Management reported no remaining Kymera Therapeutics position as of Q3 2025 after selling out during the quarter.
  • ADAR1 Capital Management sold 13,366 Kymera Therapeutics shares in Q3 2025, an estimated $583K.
  • ADAR1 Capital Management first reported a position in Kymera Therapeutics in Q1 2024 and held it in 6 quarters.
  • ADAR1 Capital Management's Kymera Therapeutics position peaked at $1.51M in Q2 2024.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2025.

Based on ADAR1 Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.